Exhibit 99.1 Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results ARLINGTON, VA – February 27, 2024 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2023. The Company achieved each of its full- year guidance metrics for 2023, as highlighted below. Full-Year Performance | | | | For the Years Ended December 31, | | | | --- | --- | --- | --- | --- | --- | | ($ in millions, except per share amo ...

Privia Health Group, Inc (NASDAQ:PRVA) Q3 2023 Earnings Call Transcript November 3, 2023 9:00 AM ET Company Participants Robert Borchert - SVP, Investor & Corporate Communications Parth Mehrotra - President and CEO David Mountcastle - CFO Conference Call Participants Joshua Raskin - Nephron Research Elizabeth Anderson - Evercore ISI Jailendra Singh - Truist Securities Richard Close - Canaccord Genuity Brian Tanquilut - Jefferies Adam Ron - Bank of America Jack Senft - William Blair Benjamin Mayo - Leerink P ...

Q3 2023 Performance Highlights - Implemented providers increased to 4,105 in Q3 2023, a 14.2% increase compared to Q3 2022[10] - Practice Collections reached $723.5 million in Q3 2023, an 18.2% increase compared to Q3 2022[10] - Adjusted EBITDA was $18.8 million in Q3 2023, a 20.0% increase compared to Q3 2022[10] - Year-to-date Practice Collections reached $2.0824 billion, compared to $1.7892 billion in the same period of 2022[29] - Year-to-date Adjusted EBITDA reached $55.0 million, compared to $46.6 million in the same period of 2022[47] Value-Based Care and MSSP Performance - Privia ACOs achieved an average aggregate savings rate of 7.6% in 2022[22] - Privia ACOs' share of shared savings was $91.2 million in 2022[23] - 77% of total MSSP lives are in downside risk tracks in 2022, compared to 0% in 2019[19] - Total annual average expenditures for MSSP 2022 Performance were improved by 8% vs Median MSSP ACO and 18% vs Total FFS Medicare[36] Expansion and Market Presence - Privia Medical Group launched in South Carolina, partnering with Greenville ENT and Allergy Associates[13] - The company has entered six new states in the last 12 months[13] - Total attributed lives reached 1.09 million, including Privia Care Partners' lives[15] Financial Position and Guidance - The company has no debt and approximately $371 million in pro forma net cash[31] - Updated FY'23 Guidance projects Practice Collections of $2.85 billion, GAAP Revenue in the mid to high end of $1.55 billion to $1.65 billion, Care Margin in the mid to high end of $350 million to $365 million, Platform Contribution above the high end of $160 million to $168 million, and Adjusted EBITDA in the mid to high end of $70 million to $74 million[32]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _______________________________ (Mark One) For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Group, Inc. (Exact Name of Registrant as Specified in Its Charter) _________________________ ...

Financial Data and Key Metrics Changes - Practice Collections increased almost 14% year-over-year, reaching $700 million in Q2 2023 [9][16] - Adjusted EBITDA rose more than 24% to $19.3 million, demonstrating strong operating leverage [9][16] - Total attributed lives increased almost 27% from a year ago, with total value-based care comprising 37% of total GAAP revenue in Q2 2023 compared to 29.6% in Q2 2022 [12][16][69] Business Line Data and Key Metrics Changes - Implemented Provider count was 3,870, up 9.3% year-over-year [16] - Care Margin increased by 18.8% for the first half of 2023 [16] - Value-based care represented 24.9% of Practice Collections in Q2 2023, up from 21.8% in Q2 2022 [69] Market Data and Key Metrics Changes - The company expanded its national footprint to include close to 3,900 implemented providers caring for over 4.4 million patients [11] - The gross provider attrition rate in 2023 has been less than 1% year-to-date, one of the lowest in the company's history [11] Company Strategy and Development Direction - The company aims to build one of the largest ambulatory care delivery networks in the nation, focusing on expanding its provider partnerships and entering new markets [8][19] - A definitive agreement was announced to enter Washington, marking the company's 13th state, in partnership with Walla Walla Clinic [9][10] - The company plans to continue investing in new markets while maintaining a strong balance sheet with approximately $318 million in cash and no debt [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage risk and deliver significant shared savings, EBITDA, and free cash flow growth [13] - The company updated its 2023 guidance to the mid to high end of initial ranges based on strong year-to-date performance [17] - Management noted that while there are challenges in the operating environment, the diversified book of business positions the company well for future growth [19] Other Important Information - A secondary offering of 42.6 million shares was completed, eliminating previous ownership by Goldman Sachs and Pamplona Capital [10] - The company has broadened its Board capabilities with new members bringing extensive healthcare industry experience [10] Q&A Session Summary Question: Utilization trends in the quarter - Management noted strong ambulatory utilization trends and a higher plateau coming out of COVID, with good performance across both fee-for-service and value-based books [24] Question: Ramp in new markets - Management reported strong early performance in new markets like North Carolina, Connecticut, and Ohio, exceeding expectations for new provider sales [29] Question: Capitated revenues and PMPM expectations - Management indicated that the PMPM for capitated revenues is expected to remain in the current range, influenced by the mix of business and risk pools [34] Question: Washington market entry - Management highlighted that they will own the tax ID and MSO entity in Washington, expecting to consolidate results from the closing date [38] Question: Value-based attributed lives growth - Management emphasized a balanced book of business and the potential for growth in attributed lives across all segments, despite some enrollment shifts [42] Question: Care management fees increase - Management attributed the increase in care management fees to strong topline growth and performance in value-based arrangements [44] Question: Investments in new markets - Management confirmed that investments in new markets are tracking on schedule and are expected to yield long-term results [48] Question: Accounts receivable increase - Management explained that the increase in accounts receivable was related to new capitation-related accruals and follows a typical annual pattern [66] Question: Virtual care strategy - Management stated that virtual care is an integral part of their strategy to optimize provider operations and improve overall economics [81]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Group, ...

Financial Data and Key Metrics Changes - Privia Health reported a 17.3% year-over-year increase in practice collections, reaching $658.9 million in Q1 2023 [83] - Adjusted EBITDA rose by 13.9% compared to Q1 last year, totaling $16.9 million [83] - Total attributed lives increased by over 22% year-over-year, driven by new ACOs in 2023 [79] Business Line Data and Key Metrics Changes - The implemented provider count grew by 10.3% year-over-year, reaching 3,716 [83] - Value-based care comprised 33.8% of total GAAP revenue in Q1 2023, up from 27.1% in Q1 2022 [83] - The company expects to add new implemented providers in Connecticut, North Carolina, and Ohio before the end of the year [79] Market Data and Key Metrics Changes - The company is entering new markets with significant total addressable market (TAM) opportunities, aiming for 400 to 500 providers over the next 4 to 5 years [9] - The health plan partner's decision to pause a capitated arrangement impacted the performance metrics, but the overall value-based book performed well [80][49] Company Strategy and Development Direction - The company aims to build one of the largest ambulatory care delivery networks in the nation, focusing on expanding its national footprint [19] - The strategy includes thoughtful movement into risk-based arrangements and partnerships with health systems [65][69] - The company plans to continue investing in new market entries and expansion, with a strong balance sheet and no debt [84] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining guidance for 2023 despite challenges, citing strong performance in the value-based book [49][84] - The company anticipates good utilization trends continuing into the rest of 2023, with a focus on prudent planning [56] - Management highlighted the importance of thoughtful risk-sharing arrangements with health plan partners [80] Other Important Information - A large secondary offering was launched, reducing the ownership of Goldman Sachs and Pamplona Capital while welcoming new long-term investors [4] - The company has a strong cash position of over $311 million, which supports its growth strategy [84] Q&A Session Summary Question: Can you clarify the timing of physician implementation? - Management indicated that they are ahead of their plan for implemented providers in new states and expect to implement some providers before the end of the year [87] Question: What is the impact of the capitated contract termination? - The health plan's decision to pause the capitated arrangement was due to operational challenges, but the company will continue to serve MA patients and reevaluate the arrangement for 2024 [80][78] Question: How are you measuring success in the Surgery Partner's partnership? - Management stated that they are looking to develop relationships and bring unique offerings to payer partners, with a focus on reducing total cost of care [71][73] Question: What are the expected margins between MSSP and capitated deals? - Management explained that the take rate on shared savings is effectively the same across both books of business, with differences in revenue recognition [100] Question: What is the outlook for new markets? - Management expects new markets to scale significantly in the coming years as they grow their provider base and attributed lives [93]

Table of Contents For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Group, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Financial Data and Key Metrics Changes - Privia Health reported a 49.1% increase in Practice Collections for 2022, reaching over $2.4 billion, with adjusted EBITDA growing 47.1% to $60.9 million [13][30][36] - The care margin increased by 28.2%, reflecting strong operational performance [13] - For 2023, Practice Collections are expected to grow by 14.5% to over $2.7 billion, with adjusted EBITDA projected to increase by 18.3% [37] Business Line Data and Key Metrics Changes - Total value-based care revenue comprised 28.5% of total GAAP revenue in 2022, up from 12.4% the previous year, indicating a significant shift towards value-based arrangements [35] - The number of Implemented Providers increased by 8.7% year-over-year to 3,606, with a strong sales pipeline for new providers [34][30] - The company added over 11,000 capitated lives in 2023, bringing the total to over 40,000, a 38% increase from year-end 2022 [11][37] Market Data and Key Metrics Changes - Privia Health expanded into four new states: North Carolina, Ohio, Connecticut, and Delaware, significantly increasing its addressable market [10][9] - The company now operates in 12 states and the District of Columbia, with over 4 million patients cared for across 950 locations [40] - The entry into new markets is expected to contribute to future growth, although initial contributions from these states are limited [77] Company Strategy and Development Direction - The company aims to build one of the largest care delivery networks in the nation, focusing on expanding its provider partnerships and attributed lives in at-risk value-based arrangements [10][9] - Privia Health's operating model allows for partnerships with various types of providers, enhancing its ability to offer solutions across all specialties [19] - The strategy includes a balanced approach across Commercial, Medicare, and Medicaid contracts, with a focus on transitioning providers to value-based care arrangements [20][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term targets of 20% growth in Practice Collections and 30% growth in adjusted EBITDA annually [37][39] - The company is focused on improving patient outcomes and lowering costs through its capitated agreements, which are still in early stages [14] - Management highlighted the importance of a disciplined approach to risk adjustment and compliance, indicating that the RADV program is not expected to have a material impact on the company [50] Other Important Information - The company maintains a strong balance sheet with $348 million in cash and no debt, with free cash flow for 2022 reported at $47.1 million [36] - Adjusted EBITDA guidance for 2023 includes $8 million to $10 million in investments for new market entries, indicating a commitment to long-term growth despite initial costs [16][80] Q&A Session Summary Question: What is included in the guidance for the new markets? - Management confirmed that attributed lives in Connecticut and Delaware are included in the guidance, although there are no implemented providers in those states yet [51][52] Question: How does the company plan to convert Privia Care Partners providers to fully implemented providers? - Management indicated that converting Privia Care Partners providers to the full stack is a high priority, with internal targets set for this transition [58] Question: What is the expected impact of the RADV program? - Management believes that the diversity of revenue mitigates risks associated with the RADV program, and they do not expect it to have a significant impact [26][50] Question: How does the company view the profitability of Medicare Advantage compared to MSSP? - Management noted that Medicare Advantage has the potential to be more profitable than MSSP, but timing for achieving similar contributions will vary [112] Question: What is the strategy for entering new markets? - The strategy remains consistent across states, focusing on establishing medical groups, risk entities, and service platforms to support growth [71][85]

Revenue Growth - Revenue for the year ended December 31, 2022, was $1,356.7 million, an increase from $966.2 million in 2021 and $817.1 million in 2020[400] - Practice Collections reached $2.42 billion in 2022, up from $1.63 billion in 2021 and $1.30 billion in 2020[400] - Revenue for the year ended December 31, 2022, was $1.36 billion, an increase of 40.4% from $966.2 million in 2021[456] Financial Performance - Adjusted EBITDA for 2022 was $60.9 million, compared to $41.4 million in 2021 and $29.4 million in 2020[400] - Adjusted EBITDA increased by 47.1% for the year ended December 31, 2022, compared to 2021, driven by organic growth and new market entry[442] - Adjusted EBITDA margin improved to 19.9% in 2022, up from 17.4% in 2021, indicating enhanced operational efficiency[443] - The company reported a net loss attributable to Privia Health Group, Inc. of $8.6 million in 2022, significantly improved from a loss of $188.2 million in 2021, a reduction of 95.4%[456] Value-Based Care (VBC) Initiatives - VBC revenue represented 28.5% of total revenue in 2022, significantly up from 12.4% in 2021 and 11.4% in 2020[405] - The company aims to enhance its VBC capabilities and accelerate the transition to VBC reimbursement across all markets[416] - The company aims to increase risk levels in value-based care programs to enhance revenue opportunities per patient over time[419] Provider and Patient Metrics - The number of Implemented Providers increased by 8.7% from 3,317 in 2021 to 3,606 in 2022, and Attributed Lives rose by 8.9% from 786,000 to 856,000 during the same period[423][426] - The launch of Privia Care Partners in January 2022 attracted approximately 350 providers and over 42,000 Attributed Lives by January 2023[421] - As of January 1, 2023, the company's capitated agreements cover healthcare services for approximately 40,600 Medicare Advantage beneficiaries[418] Cost Management - Provider expenses rose to $1.05 billion in 2022, a 44.4% increase from $727.8 million in 2021, primarily due to new at-risk capitation arrangements[459] - Cost of platform expenses decreased to $170.8 million in 2022 from $174.7 million in 2021, a reduction of 2.2%[460] - Sales and marketing expenses were $19.7 million in 2022, down 13.2% from $22.7 million in 2021, reflecting cost management efforts[461] Partnerships and Expansion - The company launched three new Accountable Care Organizations (ACOs) in early 2022 and three more in the first two months of 2023, bringing the total to ten ACOs[417] - The company entered a partnership with Surgery Partners, Inc. to expand into Montana, establishing Great Falls Clinic as an anchor practice[410] - In November 2022, a joint venture with Novant Health Enterprises was announced to launch Privia Medical Group in North Carolina[411] Cash Flow and Liquidity - Cash and cash equivalents as of December 31, 2022, were $348.0 million, supported by proceeds from the IPO and cash flows from operations[480] - Net cash provided by operating activities was $47.2 million in 2022, down from $55.1 million in 2021[485] - Net cash used in financing activities was $19.7 million for the year ended December 31, 2022, compared to net cash provided of $213.7 million in 2021, primarily due to the IPO proceeds in 2021[489] Revenue Streams - Capitated revenue for 2022 was $218.5 million, marking a new revenue stream for the company[456] - Shared savings revenue increased by 59.7% to $132.6 million in 2022, driven by growth in Medicare programs[456] - Other revenue sources include concierge services, virtual visits, and partnerships with self-insured employers, with CARES Act funds recorded as other revenue until December 31, 2021[516] Market Risks and Economic Factors - The Company faces market risks primarily from rising interest rates, with its Credit Agreement bearing interest at a floating rate linked to LIBOR plus 1.5% or ABR plus 0.5%[520] - Inflation has not materially affected the Company's operating results, although future inflation could pose risks[521]